Preventive action and anti-HCV testing revealed positive results in 1.2% (75/6,456), of patients, while 2.1% (108/5,151) of patients with various symptoms and signs were anti-HCV positive, as well as 3.4% (23/1,115) of patients with a diagnosis of fatty liver disease and 3.7% (25/1,093) of people with elevated ALT (Table 6). The gene discussed is GPT; the disease is fatty liver disease.